Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
Amoroso, V., Gallo, F., Alberti, A., Paloschi, D., Ferrari Bravo, W., Esposito, A., Cosentini, D., Grisanti, S., Pedersini, R., Petrelli, F., Berruti, A.
Published in ESMO open (01.04.2023)
Published in ESMO open (01.04.2023)
Get full text
Journal Article
56P Systemic inflammation in liver vs non-liver metastatic microsatellite stable (MSS) colorectal cancer (CRC): An analysis of 2186 patients (pts) from the observational study BMI-QoL and the phase II and III trials MACBETH, MOMA, ATEZOTRIBE, TRIBE, TRIBE2, TRIPLETE
Formica, V., Cremolini, C., Ciracì, P., Intini, R., Ferrari Bravo, W., Boccaccio, C., Pella, N., Tonini, G., Prete, A.A., Taravella, A., Russo, A., Zaniboni, A., Bergamo, F., Damonte, C., Cupini, S., Studiale, V., Cerantola, R., Brugia, M., Salvatore, L., Rossini, D.
Published in Annals of oncology (01.06.2024)
Published in Annals of oncology (01.06.2024)
Get full text
Journal Article
2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Bottiglieri, A., Ferrari Bravo, W., Rametta, A., Provenzano, L., Raggi, D., Marandino, L., Farè, E., Longo, V., Guadalupi, V., Stellato, M., Verzoni, E., Sepe, P., Claps, M., Calareso, G., Alessi, A., Cattaneo, L., Colecchia, M., Procopio, G., Necchi, A., Giannatempo, P.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
Germani, M., Moretto, R., Ros, J., Intini, R., Ghelardi, F., Vetere, G., Toledo, R., Bergamo, F., Randon, G., Elez, E., Lonardi, S., Oldani, S., Giordano, M., Rossini, D., Bravo, W. Ferrari, Ricagno, G., Vignali, P., Ugolini, C., Fontanini, G., Cremolini, C.
Published in Annals of oncology (01.06.2023)
Published in Annals of oncology (01.06.2023)
Get full text
Journal Article
27P Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase II ARCADIA trial
Sgambelluri, F., Giannatempo, P., Stellato, M., Guadalupi, V., Raggi, D., Bottiglieri, A., Claps, M., Ferrari Bravo, W., Oldani, S., Zimatore, M., Calareso, G., Alessi, A., Cattaneo, L., Verzoni, E., De Braud, F.G.M., Procopio, G., Necchi, A., Anichini, A., Mortarini, R.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article
26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)
Huber, V., Mereu, A., Lalli, L., Salsetta, J., Banfi, C., Squarcina, P., Sgambelluri, F., Mortarini, R., Stellato, M., Raggi, D., Guadalupi, V., Claps, M., Ferrari Bravo, W., Calareso, G., Alessi, A., Anichini, A., Procopio, G., Necchi, A., Rivoltini, L., Giannatempo, P.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article